News Detail
New Delhi, 16 May 2024: The Division Bench of Delhi High Court, which is hearing the petitions by pharmaceutical manufacturers against the Central government’s order prohibiting 14 fixed dose combinations (FDCs), has directed the petitioner firms and organisations to file a......
View Details
Source : Pharmabiz
Division Bench
Delhi High Court
Central government
fixed dose combinations
FDCs
Acting Chief Justice Manmohan
Lupin
Gazette of India
DTAB
Section 26A
Drugs and Cosmetics Act
Dr Reddy’s Laboratories
Abbott Healthcare
Cipla
Lupin
Alkem Laboratories
Mankind Pharma
Intas Pharmaceuticals
Seagull Laboratories
Laborate Pharmaceuticals
Laboratories Griffon
Shreya Life Sciences
Obsurge
Leeford Healthcare
CCI Products
JD Pharma
Related News
- Zydus gets warning as FDA highlights glass contamination concerns and others (12-09-2024)
- MPIDC allotted land to 36 industries in Medical Devices Park, investment of 1.8k crore (12-09-2024)
- DCC asks states and UTs to ensure implementation of revised Schedule M (12-09-2024)
- NPPA fixes retail price of 62 new drugs, extends CP of knee implants (12-09-2024)
- US FDA Issues Revised Guidance On Controlling Nitrosamine Impurities In Pharmaceuticals (12-09-2024)
- Bharat Biotech collaborates with US-based Alopexx to develop antimicrobial vaccine (12-09-2024)
- DCGI suspends permission to Entod pharma's 'Presvu Eye Drops', company to challenge order in court (11-09-2024)
- Diagnostic kits for early detection of Alzheimer’s and cancer launched (11-09-2024)
- FDI equity inflow into pharma sector grows to $236 million in Q1FY25 (11-09-2024)
- Steroid Use Could Raise Diabetes Risk (11-09-2024)